SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-019910
Filing Date
2021-02-10
Accepted
2021-02-10 17:04:05
Documents
13
Period of Report
2020-09-10
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm216138-1_8k.htm   iXBRL 8-K 26606
2 EXHIBIT 3.1 tm216138d1_ex3-1.htm EX-3.1 67304
  Complete submission text file 0001104659-21-019910.txt   286913

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA casi-20200511.xsd EX-101.SCH 3187
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE casi-20200511_lab.xml EX-101.LAB 34592
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE casi-20200511_pre.xml EX-101.PRE 22711
6 EXTRACTED XBRL INSTANCE DOCUMENT tm216138-1_8k_htm.xml XML 3730
Mailing Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850
Business Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850 240-864-2600
CASI Pharmaceuticals, Inc. (Filer) CIK: 0000895051 (see all company filings)

IRS No.: 581959440 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-20713 | Film No.: 21614945
SIC: 2836 Biological Products, (No Diagnostic Substances)